UBS Group
BBH icon

UBS Group’s VanEck Biotech ETF BBH Stock Holding History

UBS Group’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.12M Sell
16,593
-3,582
-18% -$690K ﹤0.01% 4557
2025
Q4 		$3.82M Buy
20,175
+1,374
+7% +$254K ﹤0.01% 4309
2025
Q3 		$3.12M Sell
18,801
-2,422
-11% -$395K ﹤0.01% 4519
2025
Q2 		$3.25M Sell
21,223
-6,636
-24% -$988K ﹤0.01% 4318
2025
Q1 		$4.38M Buy
27,859
+50
+0.2% +$8.12K ﹤0.01% 3920
2024
Q4 		$4.37M Buy
27,809
+751
+3% +$126K ﹤0.01% 3979
2024
Q3 		$4.8M Buy
27,058
+2,364
+10% +$419K ﹤0.01% 3112
2024
Q2 		$4.16M Sell
24,694
-604
-2% -$98.8K ﹤0.01% 3046
2024
Q1 		$4.21M Buy
25,298
+1,254
+5% +$208K ﹤0.01% 3162
2023
Q4 		$3.97M Sell
24,044
-3,021
-11% -$465K ﹤0.01% 3024
2023
Q3 		$4.21M Sell
27,065
-1,204
-4% -$192K ﹤0.01% 2743
2023
Q2 		$4.41M Sell
28,269
-2,055
-7% -$328K ﹤0.01% 2718
2023
Q1 		$4.92M Sell
30,324
-1,991
-6% -$322K ﹤0.01% 2540
2022
Q4 		$5.16M Buy
32,315
+2,186
+7% +$346K ﹤0.01% 2471
2022
Q3 		$4.24M Sell
30,129
-6,826
-18% -$1.03M ﹤0.01% 2504
2022
Q2 		$5.39M Sell
36,955
-5,990
-14% -$892K ﹤0.01% 2313
2022
Q1 		$6.96M Buy
42,945
+2,483
+6% +$402K ﹤0.01% 2237
2021
Q4 		$7.66M Sell
40,462
-1
-0% -$193 ﹤0.01% 2385
2021
Q3 		$8.18M Sell
40,463
-2,002
-5% -$420K ﹤0.01% 2207
2021
Q2 		$8.56M Buy
42,465
+1,795
+4% +$334K ﹤0.01% 2175
2021
Q1 		$7.13M Sell
40,670
-2,402
-6% -$434K ﹤0.01% 2266
2020
Q4 		$7.31M Sell
43,072
-1,400
-3% -$231K ﹤0.01% 2115
2020
Q3 		$7.21M Buy
44,472
+2,488
+6% +$405K ﹤0.01% 1881
2020
Q2 		$6.84M Sell
41,984
-2,375
-5% -$361K ﹤0.01% 1806
2020
Q1 		$5.68M Sell
44,359
-1,692
-4% -$228K ﹤0.01% 1822
2019
Q4 		$6.42M Sell
46,051
-4,978
-10% -$654K ﹤0.01% 2358
2019
Q3 		$6.02M Sell
51,029
-5,147
-9% -$640K ﹤0.01% 2204
2019
Q2 		$7.25M Sell
56,176
-248
-0.4% -$30.6K ﹤0.01% 2013
2019
Q1 		$7.25M Sell
56,424
-7,113
-11% -$899K ﹤0.01% 1920
2018
Q4 		$7.04M Sell
63,537
-4,752
-7% -$574K ﹤0.01% 1868
2018
Q3 		$9.29M Sell
68,289
-6,379
-9% -$830K ﹤0.01% 1841
2018
Q2 		$8.96M Buy
74,668
+1,502
+2% +$177K ﹤0.01% 1846
2018
Q1 		$8.81M Sell
73,166
-1,416
-2% -$178K ﹤0.01% 1810
2017
Q4 		$9.29M Sell
74,582
-107,560
-59% -$13.7M ﹤0.01% 1780
2017
Q3 		$24.4M Buy
182,142
+108,075
+146% +$14.1M 0.01% 985
2017
Q2 		$9.3M Sell
74,067
-1,441
-2% -$174K ﹤0.01% 1591
2017
Q1 		$8.99M Sell
75,508
-9,922
-12% -$1.16M ﹤0.01% 1601
2016
Q4 		$9.19M Buy
85,430
+5,239
+7% +$570K 0.01% 1567
2016
Q3 		$9.24M Sell
80,191
-1,472
-2% -$168K 0.01% 1483
2016
Q2 		$8.36M Sell
81,663
-22,142
-21% -$2.36M 0.01% 1521
2016
Q1 		$10.8M Sell
103,805
-16,175
-13% -$1.69M 0.01% 1280
2015
Q4 		$15.2M Sell
119,980
-11,884
-9% -$1.46M 0.01% 1119
2015
Q3 		$15.1M Sell
131,864
-32,406
-20% -$4.29M 0.01% 1084
2015
Q2 		$22.2M Sell
164,270
-195
-0.1% -$25.9K 0.01% 910
2015
Q1 		$21.3M Sell
164,465
-24,927
-13% -$3.13M 0.01% 913
2014
Q4 		$21.9M Buy
+189,392
New +$21.3M 0.02% 934

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
PPWM
Paragon Private Wealth Management Lexington, Kentucky $320M AUM 23.48% 1-Year Est. Return

UBS Group's BBH Position: Q1 2026 in Review

UBS Group reduced its VanEck Biotech ETF (BBH) stake by 18% in Q1 2026, selling an estimated $690K and leaving 16,593 shares worth $3.12M. The position accounts for ﹤0.01% of the portfolio, ranked #4557.

UBS Group first reported a position in BBH in Q4 2014 and has held it in 46 quarters since. The position peaked at $24.4M in Q3 2017. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

  • UBS Group held 16,593 shares of VanEck Biotech ETF worth $3.12M as of Q1 2026.
  • UBS Group sold 3,582 VanEck Biotech ETF shares in Q1 2026, an estimated $690K.
  • VanEck Biotech ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4557 holding.
  • UBS Group first reported a position in VanEck Biotech ETF in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's VanEck Biotech ETF position peaked at $24.4M in Q3 2017.
  • 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.